David J. Bearss

Halia Therapeutics, Inc. is an American company that is discovering and developing novel therapeutics to improve the lives of patients with inflammatory disorders and neurological diseases. The company is advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses. The company is headquartered in Lehi, UT. Halia Therapeutics is discovering and developing a pipeline of novel therapeutics to improve patients' lives with chronic inflammatory disorders and neurodegenerative diseases, with its initial programs targeting LRRK2 and NLRP3. The company was founded in 2017, and the CEO is David J. Bearss.

Xenter, Inc. is a privately held, investor-backed company that has launched a wireless techmed ecosystem designed to provide transformative outcomes for physicians, healthcare professionals, provider organizations, and patients. Xenter is headquartered in Draper, UT and was formed in 2020. The company's trademarks include xenter, xenfi, xmd, xenfi-hub, xmd, and physical intelligence. The company was founded by Richard J. Linder and he has been the CEO since incorporation.

Biolexis Therapeutics, Inc. provides potent and selective small molecule therapeutics. The company is based in Sandy, UT. The company was founded by Hariprasad Vankayalapati, David J. Bearss.

Canary Speech LLC engages in the development of a software that analyzes conversations using machine learning in defining neurological and cognitive diseases, ranging from Parkinson''s to dementia. The company was founded in 2016 and is headquartered in Provo, UT.

Tolero Pharmaceuticals, Inc. manufactures and markets pharmaceutical products. It is a clinical-stage biopharmaceutical company with a single-minded purpose to alleviate human suffering through the development of medicines to treat cancer and other serious human diseases. The company is headquartered in Lehi, UT.

SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA.

Montigen Pharmaceuticals, Inc. developed pharmaceutical products used for the treatment of cancer. Its products addressed oncology drug market with demonstrated preclinical activity in various solid tumor types, including pancreatic, colorectal, breast, prostate, and ovarian cancers. The company was founded in 2003 and was headquartered in Salt Lake City, UT.